Table of Contents
ISRN Obstetrics and Gynecology
Volume 2011, Article ID 575327, 8 pages
http://dx.doi.org/10.5402/2011/575327
Clinical Study

Clinicopathological Characteristics and Her-2/neu Status in Chinese Patients with Uterine Papillary Serous Carcinoma

1Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, China
2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3Department of Pathology, Fudan University Shanghai Cancer Center, China

Received 14 September 2010; Accepted 13 October 2010

Academic Editors: L. Gebrim and L. B. Twiggs

Copyright © 2011 Yulan Ren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA: Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. F. Jin, X.-O. Shu, S. S. Devesa, W. Zheng, W. J. Blot, and Y.-T. Gao, “Incidence trends for cancers of the breast, ovary, and corpus uteri in urban Shanghai, 1972–1989,” Cancer Causes and Control, vol. 4, no. 4, pp. 355–360, 1993. View at Google Scholar · View at Scopus
  3. F. Jin, S. S. Devesa, W.-H. Chow et al., “Cancer incidence trends in urban Shanghai, 1972–1994: an update,” International Journal of Cancer, vol. 83, no. 4, pp. 435–440, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Zhang, Y. B. Xiang, Z. W. Liu et al., “Cancer incidence trend among elderly people in urban Shanghai in 1973–1999,” Chinese Journal of Geriatrics, vol. 24, pp. 701–704, 2005. View at Google Scholar
  5. J. V. Bokhman, “Two pathogenetic types of endometrial carcinoma,” Gynecologic Oncology, vol. 15, no. 1, pp. 10–17, 1983. View at Google Scholar · View at Scopus
  6. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote, “Endometrial cancer,” The Lancet, vol. 366, no. 9484, pp. 491–505, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. L. Hecht and G. L. Mutter, “Molecular and pathologic aspects of endometrial carcinogenesis,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4783–4791, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. Hendrickson, J. Ross, P. Eifel, A. Martinez, and R. Kempson, “Uterine papillary serous carcinoma. A highly malignant form of endometrial adenocarcinoma,” American Journal of Surgical Pathology, vol. 6, no. 2, pp. 93–108, 1982. View at Google Scholar · View at Scopus
  9. B. M. Slomovitz, T. W. Burke, P. J. Eifel et al., “Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases,” Gynecologic Oncology, vol. 91, no. 3, pp. 463–469, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. J. K. Chan, V. Loizzi, M. Youssef et al., “Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium,” Gynecologic Oncology, vol. 90, no. 1, pp. 181–185, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Ramondetta, T. W. Burke, C. Levenback, M. Bevers, D. Bodurka-Bevers, and D. M. Gershenson, “Treatment of uterine papillary serous carcinoma with paclitaxel,” Gynecologic Oncology, vol. 82, no. 1, pp. 156–161, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. K. M. Zanotti, J. L. Belinson, A. W. Kennedy, K. D. Webster, and M. Markman, “The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma,” Gynecologic Oncology, vol. 74, no. 2, pp. 272–277, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. P. Casalini, M. V. Iorio, E. Galmozzi, and S. Ménard, “Role of HER receptors family in development and differentiation,” Journal of Cellular Physiology, vol. 200, no. 3, pp. 343–350, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. D. J. Slamon, G. M. Clark, and S. G. Wong, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Google Scholar · View at Scopus
  15. M. F. Press, L. Bernstein, P. A. Thomas et al., “HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas,” Journal of Clinical Oncology, vol. 15, no. 8, pp. 2894–2904, 1997. View at Google Scholar · View at Scopus
  16. M. J. Ellis, A. Coop, B. Singh et al., “Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial,” Journal of Clinical Oncology, vol. 19, no. 18, pp. 3808–3816, 2001. View at Google Scholar · View at Scopus
  17. S. Paik, J. Bryant, C. Park et al., “erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer,” Journal of the National Cancer Institute, vol. 90, no. 18, pp. 1361–1370, 1998. View at Google Scholar · View at Scopus
  18. E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1673–1684, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. B. M. Slomovitz, R. R. Broaddus, T. W. Burke et al., “Her-2/neu overexpression and amplification in uterine papillary serous carcinoma,” Journal of Clinical Oncology, vol. 22, no. 15, pp. 3126–3132, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. D. Santin, S. Bellone, S. Van Stedum et al., “Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization,” Gynecologic Oncology, vol. 98, no. 1, pp. 24–30, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. A. D. Santin, S. Bellone, M. Gokden et al., “Overexpression of HER-2/neu in uterine serous papillary cancer,” Clinical Cancer Research, vol. 8, no. 5, pp. 1271–1279, 2002. View at Google Scholar · View at Scopus
  22. S. A. Thalberg, “New gynecologic cancer staging,” Obstetrics and Gynecology, vol. 76, no. 1, p. 158, 1990. View at Google Scholar · View at Scopus
  23. C. Morrison, V. Zanagnolo, N. Ramirez et al., “HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients,” Journal of Clinical Oncology, vol. 24, no. 15, pp. 2376–2385, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. B. Saffari, L. A. Jones, A. El-Naggar, J. C. Felix, J. George, and M. F. Press, “Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival,” Cancer Research, vol. 55, no. 23, pp. 5693–5698, 1995. View at Google Scholar · View at Scopus
  25. Y. L. Ren, H. Y. Wang, L. Shen, and W. T. Yang, “Clinical and pathologic analysis of 33 cases of uterine papillary serous carcinoma,” Zhonghua Fu Chan Ke Za Zhi, vol. 41, no. 12, pp. 817–821, 2006. View at Google Scholar · View at Scopus
  26. A. D. Santin, S. Bellone, E. R. Siegel et al., “Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer,” American Journal of Obstetrics and Gynecology, vol. 192, no. 3, pp. 813–818, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. M. M. Zhang, M. K. Cheung, K. Osann et al., “Improved survival of Asians with corpus cancer compared with whites: an analysis of underlying factors,” Obstetrics and Gynecology, vol. 107, no. 2 I, pp. 329–335, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. T. A. Grushko, V. L. Filiaci, A. J. Mundt, K. Ridderstråle, O. I. Olopade, and G. F. Fleming, “An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group Study,” Gynecologic Oncology, vol. 108, no. 1, pp. 3–9, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. R. Halperin, S. Zehavi, L. Habler, E. Hadas, I. Bukovsky, and D. Schneider, “Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium,” European Journal of Gynaecological Oncology, vol. 22, no. 2, pp. 122–126, 2001. View at Google Scholar · View at Scopus
  30. T. P. Díaz-Montes, H. Ji, A. E. Smith Sehdev et al., “Clinical significance of Her-2/neu overexpression in uterine serous carcinoma,” Gynecologic Oncology, vol. 100, no. 1, pp. 139–144, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. J. Prat, E. Oliva, E. Lerma, M. Vaquero, and X. Matias-Guiu, “Uterine papillary serous adenocarcinoma: a 10-case study of p53 and c-erbB-2 expression and DNA content,” Cancer, vol. 74, no. 6, pp. 1778–1783, 1994. View at Publisher · View at Google Scholar · View at Scopus
  32. A. D. Santin, S. Bellone, S. Van Stedum et al., “Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma,” Cancer, vol. 104, no. 7, pp. 1391–1397, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. G. F. Fleming, M. A. Sill, J. T. Thigpen et al., “Phase II evaluation of Trastuzumab in patients with advanced or recurrent endometrial carcinoma: a report on GOG 181B,” Journal of Clinical Oncology, vol. 22, p. 453, 2003. View at Google Scholar
  34. J. A. Villella, S. Cohen, D. H. Smith, H. Hibshoosh, and D. Hershman, “HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications,” International Journal of Gynecological Cancer, vol. 16, no. 5, pp. 1897–1902, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus